Fc-fusions are homodimers in which an Fc domain of an antibody is covalently linked to another protein. The fusion partner is usually directly attached to the flexible hinge (as shown), the length and sequence of which varies between different IgG subclasses.

Fc-fusion proteins are composed of Fc region of IgG antibody (Hinge-CH2-CH3) and a desired linked protein. Fc region of Fc-fusion proteins can bind to neonatal Fc receptor (FcRn) thereby rescuing it from degradation. The first therapeutic Fc-fusion protein was introduced for the treatment of AIDS.

In this review, we highlight the wide range of analytical strategies used to fully characterize Fc-fusion proteins. We also present case studies on the structural assessment of all commercially available Fc-fusion proteins, based on the features and critical quality attributes of their ligand-binding domains.

Among the other targets successfully modulated by marketed Fc-fusion proteins or peptides are CD2 (alefacept), CD80/86 (abatacept, belatacept) and thrombopoietin receptor (romiplostim). The primary reason for fusion of a binding moiety with Fc is half-life extension.

Fc fusion protein refers to a new type of recombinant protein produced by fusing the target protein with the Fc fragment of immunoglobulin (such as IgG, IgA, etc.). Utilizing the long-acting principle of fc fusion protein, the half-life of the drug in plasma can be extended...

Since the first description in 1989 of CD4-Fc-fusion antagonists that inhibit human immune deficiency virus entry into T cells, Fc-fusion proteins have been intensely investigated for their effectiveness to curb a range of pathologies, with several notable recent …

We describe high titer expression of Fc-fusion proteins using FUJIFILM Diosynth Biotechnologies’ Apollo™ X platform coupled with integrated quality assessments, enhancing our support for clients through the predicted growth in Fc -fusion clinical applications .

Jun 21, 2018 · Fc fusion proteins on the market include etanercept (Enbrel®), abatacept (Orencia®), aflibercept (Eylea®), rilonacept (Arcalyst®), romiplostim (Nplate®), belatacept (Nulojix®), factor VIII Fc (Eloctate®), and factor IX Fc (Alprolix®).

Since the first description in 1989 of CD4‐Fc‐fusion antagonists that inhibit human immune deficiency virus entry into T cells, Fc‐fusion proteins have been intensely investigated for their effectiveness to curb a range of pathologies, with several notable recent …

This article discusses approved Fc-fusion therapeutics, novel Fc-fusion proteins and FcRn-dependent delivery approaches in development, and how engineering of the FcRn–Fc interaction can generate longer-lasting and more effective therapeutics.